New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 11, 2014
18:01 EDTICPTNIH says patients on Intercept drug had more 'bad' cholesterol, WSJ says
Late Friday, the Wall Street Journal reported that the National Institutes of Health, NIH, said patients that were treated with Intercept Pharmaceuticals's experimental liver-disease drug obeticholic acid, or OCA, in a clinical trial experienced more abnormal cholesterol levels than those who were given a placebo. The NIH, said it was making this information available to give "broader context for the findings" of the trial, added the Wall Street Journal. Shares of Intercept traded down 6% in after-hours trading on Friday evening after the report. Reference Link
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
09:15 EDTICPTIntercept recent weakness a buying opportunity, says Summer Street
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use